Jerome M. Adams, MD, MPH; Janet S. Wright, MD
has multimedia
has audio
JAMA. 2020;324(18):1825-1826. doi:10.1001/jama.2020.20356
This Viewpoint from the US Surgeon General’s office announces the 2020 release of the Surgeon General’s Call to Action to Control Hypertension and summarizes its key goals and recommendations aimed at making hypertension control a national public health priority and ensuring communities and patients have the resources to achieve it.
-
Conversations with Dr Bauchner:
The Surgeon General's Call to Action to Control Hypertension
Christopher W. Seymour, MD, MSc; Erin K. McCreary, PharmD; Jacob Stegenga, PhD
free access
has active quiz
has multimedia
has audio
JAMA. 2020;324(18):1827-1828. doi:10.1001/jama.2020.20271
This Viewpoint discusses the tensions between rapid adoption of interventions for coronavirus disease 2019 (COVID-19) before adequate evidence justifies their use and therapeutic nihilism, and argues for sensible medicine between the 2, which favors usual care, disfavors unnecessary interventions, but embraces rapid scientific evaluation with clinical translation of options proven effective.
-
Conversations with Dr Bauchner:
Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic
-
Conversations with Dr Bauchner:
Coronavirus Critical Care Update With Lennie Derde and Christopher Seymour
COVID-19: Beyond Tomorrow
Kristine Olson, MD, MSc; Tait Shanafelt, MD; Steve Southwick, MD
free access
has active quiz
JAMA. 2020;324(18):1829-1830. doi:10.1001/jama.2020.20275
This Viewpoint discusses how disruptions from the coronavirus disease 2019 (COVID-19) pandemic can set the stage for beneficial personal and organizational change, and proposes steps that can be taken to catalyze the posttraumatic growth process.
Rachel E. Sachs, JD, MPH; Julie M. Donohue, PhD; Stacie B. Dusetzina, PhD
free access
JAMA. 2020;324(18):1831-1832. doi:10.1001/jama.2020.19325
In the context of declining state Medicaid revenues and rising enrollment related due to coronavirus disease 2019, this Viewpoint proposes policy and payment reforms related to mandated drug coverage and manufacturer rebates that could assist states financially while maintaining patient access to life-saving medications.